Overview

This trial is active, not recruiting.

Conditions rheumatoid arthritis, arthritis, psoriatic, ankylosing spondylitis
Treatments systemic non-biological treatments, anti-tnf biologics, golimumab, non-anti-tnf biologics, general population
Phase phase 4
Target TNF-alpha
Sponsor Janssen Biotech, Inc.
Start date April 2009
End date September 2017
Trial size 1000 participants
Trial identifier NCT01081717, CNTO148ART4002, CR016720

Summary

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan.The objective of this study is to estimate the rate of serious infections, tuberculosis, malignancies, and other outcomes in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients treated with golimumab, anti-tumor necrosis factor (TNF) biologics, non-anti-TNF biologics, or systemic non-biological treatments.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
golimumab as prescribed
golimumab
as prescribed
anti-TNF biologics as prescribed
anti-tnf biologics
as prescribed
non-anti-TNF biologics as prescribed
non-anti-tnf biologics
as prescribed
systemic non-biological treatments as prescribed
systemic non-biological treatments
as prescribed
general population non-treated cohort
general population
non-treated cohort

Primary Outcomes

Measure
Estimate incidence of serious infections, malignancies, and other selected outcomes in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis initiating golimumab and other biological and systemic non-biological treatment
time frame: The study will be approximately 8 years in duration

Eligibility Criteria

Male or female participants up to 99 years old.

Inclusion Criteria: - Complete medical coverage and pharmacy benefits - Six months of continuous enrollment prior to the date of cohort entry Exclusion Criteria: - Participants will be excluded if they do not have information on age, gender or enrollment

Additional Information

Official title A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments
Description The participants included in this study will be drawn from the Ingenix Normative Health Informatics Database, a proprietary research database containing claims and enrollment data dating back to 1993 for members of a large, geographically diverse US health plan. This study will include cohorts of participants who have claims consistent with a diagnosis of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis and who initiate golimumab, anti-TNF biologics, non-anti-TNF biologics, or systemic non-biological treatments. Participants will be identified by claims bearing codes for dispensed drugs, procedures or diagnoses and followed after the launch of golimumab for up to 8 years. A sample of enrolled health plan members without claims evidence of diagnosis or treatment of Rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis will also be selected. The claims database will be used to estimate the incidence of the primary outcomes of serious infections, tuberculosis (TB) and non-TB mycobacterial infections, malignancies such as lymphoma, and other selected outcomes. No study agents will be administered in this study. All participants will receive standard-of-care treatment as prescribed by their physician
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Janssen Biotech, Inc..